Gene Therapy, Pharma

Voyager bags a ‘transformational’ $1.8B gene therapy pact with Neurocrine

Neurocrine has bellied up to the deal table, snagging commercial rights to 4 gene therapy development programs at Voyager Therapeutics — including their lead mid-stage treatment for Parkinson-s disease — for $165 million in cash split between an upfront payment and a $50 million equity stake, plus another $1.5 billion in milestone money.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,200+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->